Local-region treatment comparison following conversion therapy of hepatocellular carcinoma: a period and age-dependent analysis
MWA might be acceptable as an alternative to SR in first-line therapeutic scheme after TACE conversion therapy for uHCC, especially, for the aged <45 years cohorts.
Authors
- Wang Yao (ORCID: https://orcid.org/0000-0003-1776-3031)
- Shu Zhao
- Weiwei Xing
- Mengxuan Zuo (ORCID: https://orcid.org/0000-0003-3589-7316)
- Chun Hui Li
- Jiahui Hu (ORCID: https://orcid.org/0000-0002-6856-9899)
- Xinyu Yang (ORCID: https://orcid.org/0000-0002-4124-7144)
- Peng Song
Institutions
- Tianjin University of Traditional Chinese Medicine (CN)
- Beijing Institute of Education (CN)
- Sun Yat-sen University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Chinese PLA General Hospital (CN)
- Tangshan People's Hospital (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Sun Yat-sen University Cancer Center (CN)
- Institute of Basic Medical Sciences of the Chinese Academy of Medical Sciences
Publication Details
- Journal
- Therapeutic Advances in Medical Oncology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1177/17588359251316665
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00